The firm said the move would bring together its three subsidiaries: Redx anti-infectives and Redx immunology which are already based at the site; and Redx oncology, which is currently based at Royal Liverpool Hospital.
The news follows a day after Redx announced a new share offering.
A spokesman for the firm told us "Redx is leasing lab space, not buying the building so the Alderley Park relocation is un-related to the recent fundraising."
He added that: "All staff at Redx in Liverpool will be retained – no jobs will be lost and no one is leaving the business. Alderley Park is reasonably local to Liverpool."
Redx plans to complete the move by the end of the year.
The Alderly Park site was sold by AstraZeneca to Manchester Science Parks – a public-private partnership – in 2014,
Redx CEO Neil Murray said: “Alderley Park’s high specification laboratories and superlative facilities present a commercially attractive solution as we seek to provide the best infrastructure and environment for our staff.
“The site has a great history as a global leader in cancer research and we look forward to adding Redx drugs to the roll call of successful cancer therapies that ICI and AstraZeneca produced over the years.”